Skip to main content
Journals

Socially Transformative Aesthetics: Real-World Evidence of Positive First Impressions After Pan-Facial Aesthetic Treatments

Aesthetic Surgery Journal Open Forum
Aesthetic Surgery Journal Open Forum

Authors: Steven Dayan, MD , Julia K Garcia, PhD, MS , Nazanin Ashourian, PhD , Sara Sangha, PhD , Vaishali Patel, PharmD, MS

Abstract: Minimally invasive, pan-facial aesthetic treatments rejuvenate and improve facial appearance and may impact social interactions and perceptions. This observational pilot study used video recordings and in-person evaluations to assess social perceptions of participants before and after pan-facial treatment. Adults receiving pan-facial injectable treatments (ie, onabotulinumtoxinA [Botox Cosmetic, Allergan Aesthetics, Westport, Ireland], hyaluronic acid fillers [Juvéderm; Allergan Aesthetics, Irvine, California], or both) were invited to participate. Three measures were developed to assess perceptions of attractiveness, approachability, naturalness, trustworthiness, healthiness, and age from nonclinical observer, patient participant, and clinician perspectives: the Pan-Facial Treatment Outcome Survey, the Participant Perception of Appearance, and the Clinician Perception of Appearance. Twenty-seven participants received treatment and provided video recordings, with 16 videos (n = 8 participants) selected for the study; 298 individuals enrolled as nonclinical observers. Compared with baseline assessments, nonclinical observer–reported posttreatment scores were significantly higher for perceptions of attractiveness, approachability, naturalness, healthiness, and perceived age (all P values < .05). Posttreatment participant- and clinician-reported scores were significantly higher for the same domains as well as trustworthiness (all P values < .05). Compared with baseline, participants and the clinician perceived participants as younger compared to their actual age (3.6 years younger and 2.5 years younger, respectively), and nonclinical observers perceived participants as within 6 months of their actual age after pan-facial treatment. Pan-facial treatments may positively impact social perceptions and self-assessments of facial appearance. These benefits extend beyond physical appearance, including improving overall social interactions and personal well-being.

JOURNAL ARTICLE

Related Articles

AbobotulinumtoxinA (aboBoNT-A; Dysport®) is approved in China for treating glabellar lines (GLs) with fast onset of action (median: 2 days) and effectiveness up to 6 months (Chinese pivotal trial data), but real-world data remain limited. This study’s primary objective is to assess patient satisfaction following 3 cycles of aboBoNT-A treatment for moderate-to-severe GLs in a real-world setting.
Resident-run clinics (RRCs) have become an important component of plastic surgery training. This study evaluates outcomes from a longitudinal RRC focused on neuromodulator and soft tissue filler injections over a 5-year period. The aim of this study was to assess clinical outcomes, patient retention, resident experience by postgraduate year (PGY) level, and the safety of RRCs as a training model.
Melasma is a chronic, relapsing hyperpigmentation disorder that is difficult to treat, particularly in Fitzpatrick skin types III-V, where energy-based devices frequently induce postinflammatory hyperpigmentation (PIH). Radiofrequency microneedling (RFMN) has emerged as a promising alternative because it targets dermal pathology while minimizing epidermal injury.
Upper facial lines (UFLs), including glabellar frown lines (GFLs), horizontal forehead lines (HFLs), and lateral canthal lines (LCLs) are prevalent aesthetic concerns addressed with botulinum neurotoxin type A (BoNT-A). IncobotulinumtoxinA, a highly purified BoNT-A formulation, is utilized for simultaneous UFLs treatment; yet, comprehensive synthesized evidence is limited.